A Risk-Benefit Assessment of Tacrolimus in Transplantation
- 1 May 1995
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 12 (5) , 348-357
- https://doi.org/10.2165/00002018-199512050-00006
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations.1995
- Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients.1995
- Comparison of Different Assays for the Quantitation of FK 506 Levels in Blood or PlasmaTherapeutic Drug Monitoring, 1994
- Chronic allograft rejection: An updateClinical Transplantation, 1994
- FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects.1994
- Conversion from cyclosporin to FK 506 after liver transplantationTransplant International, 1993
- TacrolimusDrugs, 1993
- Anaemia associated with FK 506 immunosuppressionThe Lancet, 1993
- Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine.1991
- Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report.1988